Press Releases
Biological Dynamics, Inc., a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform. ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
Media Spotlight
Extracellular vesicles (EVs) are tiny bubbles released by cells containing proteins and genetic material, offering insights into cell health and potential for disease detection. Scientists are exploring ways to customize EVs to deliver therapeutic agents to specific sites, potentially revolutionizing treatment for conditions like cancer and spinal cord injuries.
In the dynamic field of cancer research, the hunt for breakthroughs in early disease detection is critical for improving patient outcomes. Exosomes are garnering attention for their potential in cancer diagnostics. The emergence of exosomes and their cargo as important biomarkers in disease monitoring, early discovery, and precision medicine may herald a transformative era in patient care.